Importantly, increased ENO-1+ CD81+ EVs in the patient serum before treatments can distinguish patients with Ewing sarcoma from healthy individuals with an area under the curve of 0.92 and reflected the tumor burden in Ewing sarcoma patients during multidisciplinary treatments [71]. This evidence concerns the gene ENO1 and neoplasm.